Scientists Discover Cause Of Leukaemia That Halted Treatment Trial For 'Baby-in-a-Bubble' SyndromeOctober 16, 2003Medical Research Council (MRC) scientists have helped establish the cause of the leukaemia which developed in two young patients taking part in a pioneering gene therapy trial to treat the fatal 'baby-in-a-bubble' syndrome, severe combined immunodeficiency (X-SCID). The trial at the Necker-Enfants Malades clinic in Paris was stopped last year due to the higher than expected number of cases of leukaemia amongst the eight children taking part. After three years of successful gene therapy for X-SCID, leukaemia occurred in the two youngest patients undergoing treatment. Contributing to the international effort to establish quickly why the leukaemia developed, the scientists reveal in the journal Science that in the cases of the two boys, the gene therapy corrected the faulty gene but also activated a cancer-causing gene called LMO2. The scientists suggest that a number of factors might explain why this occurred at a very much higher frequency than expected and that by modifying these factors, scientists will be able to deliver a gene therapy to treat X-SCID which has a much lower risk of causing leukaemia. X-SCID is a genetic disease only found in boys. Those with X-SCID, or 'baby-in-a-bubble' syndrome, are born without an immune system forcing them to live in sterile conditions or risk picking up a life-threatening infection. The disease is caused by a single mutated gene and in the absence of a matched bone marrow donor there is no cure other than gene therapy. Lead MRC researcher, Dr Terry Rabbitts of the MRC Laboratory of Molecular Biology, said: "Cancer is a possible side effect of gene therapy, so any research which will help scientists to modify the treatment to reduce that risk is of great importance. "Although it is anguishing for parents to expose their children to the chance of developing cancer, the benefits of gene therapy for this devastating disease greatly outweigh the risks of the disease itself as X-SCID can only be treated if a matched bone marrow donor is available." Both children who developed leukaemia during the trial underwent treatment for their cancer with chemotherapy and bone marrow transplants. They are alive and well, and in complete clinical remission. Up to one in 50,000 births in the UK are affected by X-SCID. Dr Rabbitts worked on this project in collaboration with scientists from the Babraham Institute and across Europe and the USA. ENDS | |||||||||||||||||||||
|
Related Gene Therapy Current Events and Gene Therapy News Articles Gene therapy corrects sickle cell disease in laboratory study Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology. Science teams at Cold Spring Harbor Laboratory identify 13 new tumor-suppressor genes in liver cancer Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise. At Cold Spring Harbor Laboratory (CSHL), five different research groups have now combined their expertise to speed up the rate of discovering cancer-related genes and validating their function in living animals. New gene silencing pathway found in plants Biologists at Washington University in St. Louis have made major headway in explaining a mechanism by which plant cells silence potentially harmful genes. First trial of gene therapy for advanced heart failure shows promising results Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity. Researchers use chemical from medicinal plants to fight HIV Like other kinds of cells, immune cells lose the ability to divide as they age because a part of their chromosomes known as a telomere becomes progressively shorter with cell division. As a result, the cell changes in many ways, and its disease fighting ability is compromised. A double-barreled immune cell approach for neuroblastoma Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online today in the journal Nature Medicine. Scientist clears hurdles for muscular dystrophy therapy Approximately 250,000 people in the United States have some form of muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common type of the disease, predominantly affecting males. Study may explain exercise-induced fatigue in muscular dystrophies A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease. MicroRNAs make for safer cancer treatments Viruses -- long regarded solely as disease agents -- now are being used in therapies for cancer. Concerns over the safety of these so-called oncolytic viruses stem from their potential to damage healthy tissues. Keeping herpes infection in check: Pitt researchers describe immune system strategies Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects. More Gene Therapy Current Events and Gene Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||